Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms
NCT ID: NCT03974789
Last Updated: 2025-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
380 participants
OBSERVATIONAL
2019-07-01
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Salivary Cortisol Measurement in Corticotrope Deficiency Substitution With Hydrocortisone.
NCT05457296
Real-time Monitoring of Cortisol - Comparison of Cortisol Levels in Four Biological Fluids
NCT06008184
Contribution of Salivary Cortisol in the Detection of Infra-clinic Cortisol Adenoma (ACIC)
NCT01156519
Assessment of Diurnal Salivary Cortisol Production in COVID-19
NCT04988269
Establishment and Clinical Application of Reference Intervals of Salivary Cortisol
NCT07168122
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Suspected Cushing Disease
Blood test
Plasma cortisol level test
24-hour Urine test
Urinary free cortisol test
Saliva swab
salivette® for salivary cortisol quantification
Dexamethasone test
Dectancyl® 2 x 0.5 mg tablets (total 1 mg)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood test
Plasma cortisol level test
24-hour Urine test
Urinary free cortisol test
Saliva swab
salivette® for salivary cortisol quantification
Dexamethasone test
Dectancyl® 2 x 0.5 mg tablets (total 1 mg)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient must be a member or beneficiary of a health insurance plan
Exclusion Criteria
* The patient has a cardiovascular or metabolic state against the indication of dexamethasone
\- Patient with DFG \< 30 ml/min/1.73 m2
* The patient has suffered urinary incontinence rendering 24-hour urinary collection impossible or non-interpretable
* The patient has a urinary catheter
* The patient is taking corticoids (oral, inhaled, intra-venous or cutaneous)
.Patient exposed to interfering treatments (Itraconazole, ritonavir, megestrol acetate, medroxyprogesterone acetate, TSH, estrogen-progestogen pill, hormonal coil)
* The subject is in a period of exclusion determined by a previous study
* The subject opposes their participation in the study
* It is impossible to give the subject informed information
* The patient is under safeguard of justice or state guardianship
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nīmes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David de Brauwere
Role: PRINCIPAL_INVESTIGATOR
CHU Nimes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Nimes
Nîmes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIMAO/2018-03/DPDB-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.